Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
70.5 CHF | -0.56% |
|
-0.84% | +38.51% |
06-18 | Switzerland's Cosmo Pharmaceuticals Receives Drug Registration Certificate for Lumeblue in China | MT |
06-03 | Cosmo Pharmaceuticals Swings to Loss in FY23; Revenue Down | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.51% | 1.27B | |
+55.19% | 815B | |
+45.88% | 654B | |
-6.09% | 354B | |
+21.92% | 337B | |
+18.34% | 247B | |
+2.66% | 229B | |
+13.23% | 219B | |
+10.86% | 171B | |
-2.78% | 159B |
- Stock Market
- Equities
- COPN Stock
- News Cosmo Pharmaceuticals N.V.
- Cosmo Pharmaceuticals N.V. Appoints John Manieri as Head of Cosmo's Investor Relation Activities and Head of the Investment Committee as of July 1, 2017